Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells

Mikinori Miyazaki, Yoshiki Akatsuka, Tetsuya Nishida, Nobuharu Fujii, Akio Hiraki, Kazuma Ikeda, Kunio Tsujimura, Kiyotaka Kuzushima, Yasuo Morishima, Shigeki Sato, Ryuzo Ueda, Toshitada Takahashi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We have shown previously that KIAA0223, a gene encoding a minor histocompatibility antigen, HA-1, whose expression was believed to be restricted to the hematopoietic cells, is aberrantly expressed in some solid tumor cell lines. However, its significance in tumor immunity needs to be determined. Cytotoxic activity of HA-1H-specific cytotoxic T lymphocytes (CTLs) was assessed against solid tumor cell lines expressing KIAA0223 using 51Cr release assays. Five of seven cell lines were lysed when HLA-A*0201 was adequately expressed. One of the two CTL-resistant cell lines became susceptible after treatment with IFN-γ and TNF-α, while the other was lysed only after pulsing with HA-1H peptide. In most cell lines tested, HA-1H peptide was properly generated and presented for recognition by the CTL. However, impaired antigen processing and presentation observed in this study may result in escape from CTL recognition in vivo, as well as in vitro, as observed in this study.

Original languageEnglish
Pages (from-to)198-201
Number of pages4
JournalClinical Immunology
Volume107
Issue number3
DOIs
Publication statusPublished - Jun 1 2003

    Fingerprint

Keywords

  • Cytotoxic T lymphocyte
  • HA-1
  • Minor histocompatibility antigen
  • Solid tumor
  • Transporter associated with antigen processing

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Miyazaki, M., Akatsuka, Y., Nishida, T., Fujii, N., Hiraki, A., Ikeda, K., Tsujimura, K., Kuzushima, K., Morishima, Y., Sato, S., Ueda, R., & Takahashi, T. (2003). Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. Clinical Immunology, 107(3), 198-201. https://doi.org/10.1016/S1521-6616(03)00065-2